Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Redeye: Magle Chemoswed Q2 - Delays weigh down the quarter’s results

Magle Chemoswed Holding

Redeye provides a research update following the Q2 report recently published by Magle. The report came in significantly below our expectations following delayed high-value orders, raw material shortages, and non-recurring integration costs. However, while the shortfalls in the company’s financial performance are disappointing, we believe them to be primarily one-off events and anticipate Magle’s growth to pick up again in Q3. That said, we make some adjustments to our estimates following the report and lower our fair value range (SEK19 – SEK57) with a revised base case valuation of SEK40 (45).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Magle Chemoswed Q2 - Delays weigh down the quarter’s results

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.